APLS vs JCI · rev $1.00B vs P/E 44, rev $23.60B
Apellis Pharmaceuticals Inc (APLS) versus Johnson Controls International PLC (JCI) — a side-by-side from cached financials, not a winner call.
Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on US.
Johnson Controls International PLC (JCI) is a building products & equipment company listed on NYSE.
Latest reported APLS revenue for 2025-12-31 was $1.00B. Net income was $22.4M. Revenue was up 28.5% from 2024-12-31 to 2025-12-31. APLS currently screens at market cap $2.29B.
Latest reported JCI revenue for 2025-09-30 was $23.60B. Net income was $3.51B. JCI currently screens at market cap $87.62B and trailing P/E 43.9.
APLS currently screens at market cap $2.29B. JCI currently screens at market cap $87.62B and trailing P/E 43.9.
Not investment advice. Open the APLS and JCI stock pages for the full models.
Not investment advice.